Celebrating 20 Years of IP Excellence

px Novo Nordisk.svg

A Patently Generic Win

This post was first published on April 23, 2012. In a landmark decision on a generic drug-maker’s ability to introduce a generic drug for uses not indicated on the branded product’s label, the US Supreme Court ruled in favour of Caraco Pharmaceutical Laboratories, a unit of Sun Pharmaceutical Industries, in its patent litigation against Novo Nordisk over Caraco’s generic version of Prandin, repaglinide tablets, a blood glucose lowering drug. The drug in question, Prandin, generically known as repaglinide, is used…

Read more

image for Roche’s backbone rendered brittle by Indian Patent Office

Roche’s backbone rendered brittle by Indian Patent Office

The Chennai Patent Office revoked Hoffmann-La-Roche’s patent on its osteoporosis drug, Bonviva, in response to post grant opposition filed by Indian drug maker, Cipla Global Ltd. The drug in question comprises Ibandronate Sodium, used to treat patients suffering from metastatic cancer, associated skeletal fractures and osteoporosis and also for the treatment and prevention of osteoporosis in post-menopausal women. Osteoporosis is the progressive bone disease caused by decrease in bone mass making bones extremely weak and fragile, leading to increased risk of…

Read more